Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) — Tangible Net Worth Ratio
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has a Tangible Net Worth Ratio of 99.4% as of March 2026. This metric is calculated by deducting intangible assets (CN¥31.36 Million) from net assets (CN¥5.67 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See net assets of Wuhan Easy Diagnosis Biomedicine Co Ltd for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Tangible Net Worth Ratio (2011–2025)
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 99.4%, reflecting net assets of CN¥5.67 Billion with intangible assets of CN¥31.36 Million CNY. Also explore Wuhan Easy Diagnosis Biomedicine Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Wuhan Easy Diagnosis Biomedicine Co Ltd market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 99.5% | CN¥5.66 Billion | CN¥26.54 Million | CN¥5.98 Billion | ▼ -0.2 pp |
| 2024 | 99.7% | CN¥6.02 Billion | CN¥17.30 Million | CN¥6.59 Billion | ▼ 0.0 pp |
| 2023 | 99.7% | CN¥6.29 Billion | CN¥17.70 Million | CN¥7.39 Billion | ▼ 0.0 pp |
| 2022 | 99.8% | CN¥6.77 Billion | CN¥16.86 Million | CN¥9.19 Billion | ▲ +0.3 pp |
| 2021 | 99.4% | CN¥2.85 Billion | CN¥16.59 Million | CN¥3.42 Billion | ▲ +0.9 pp |
| 2020 | 98.5% | CN¥1.11 Billion | CN¥16.93 Million | CN¥1.43 Billion | ▲ +1.3 pp |
| 2019 | 97.2% | CN¥615.62 Million | CN¥17.39 Million | CN¥638.42 Million | ▲ +0.2 pp |
| 2018 | 97.0% | CN¥592.59 Million | CN¥17.98 Million | CN¥617.15 Million | ▲ +4.6 pp |
| 2017 | 92.4% | CN¥242.93 Million | CN¥18.49 Million | CN¥256.54 Million | ▼ -6.2 pp |
| 2016 | 98.6% | CN¥175.08 Million | CN¥2.51 Million | CN¥197.15 Million | ▲ +0.9 pp |
| 2015 | 97.6% | CN¥115.39 Million | CN¥2.74 Million | CN¥133.96 Million | ▲ +3.3 pp |
| 2014 | 94.3% | CN¥49.59 Million | CN¥2.81 Million | CN¥61.01 Million | ▲ +15.8 pp |
| 2013 | 78.6% | CN¥13.60 Million | CN¥2.91 Million | CN¥23.79 Million | ▼ -21.4 pp |
| 2012 | 100.0% | CN¥1.42 Million | CN¥0.00 | CN¥4.66 Million | ▲ +0.0 pp |
| 2011 | 100.0% | CN¥21.45K | CN¥0.00 | CN¥1.96 Million | — |